| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
| Targets |
Teclozan targets Entamoeba histolytica, the protozoan parasite responsible for amebiasis. The compound's mechanism involves amebicidal activity against the trophozoite form of the parasite in the intestinal lumen. The exact molecular target of teclozan is not fully elucidated, but it is believed to interfere with essential metabolic processes or membrane integrity of the parasite.
|
|---|---|
| ln Vitro |
Teclozan demonstrates in vitro amebicidal activity against Entamoeba histolytica. The compound's activity is assessed in standard antiprotozoal susceptibility assays measuring inhibition of parasite growth and viability. Its activity is concentration-dependent, with effective concentrations determined from dose-response curves.
|
| ln Vivo |
Teclozan is used in vivo for the treatment of intestinal amebiasis. It acts locally in the intestinal lumen to eliminate Entamoeba histolytica trophozoites. The compound is effective against the intestinal form of amebiasis and is used clinically as an amebicide.
|
| Enzyme Assay |
In vitro antiprotozoal assays for teclozan involve culturing Entamoeba histolytica trophozoites in the presence of varying concentrations of the compound. Amebicidal activity is assessed by measuring inhibition of parasite growth, viability, or motility using microscopy or metabolic assays.
|
| Cell Assay |
In vitro cellular assays for teclozan involve treating Entamoeba histolytica cultures with varying concentrations of the compound and assessing parasite viability and growth inhibition. The compound's selectivity for the parasite over host cells can be evaluated using mammalian cell lines.
|
| Animal Protocol |
In vivo animal experiments for teclozan are not extensively documented in the available literature. The compound is used clinically as an amebicide, and its efficacy has been established through clinical use rather than extensive animal studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for teclozan indicate that it acts locally in the intestinal lumen and is poorly absorbed systemically. The compound has a molecular weight of 366.06. Its limited systemic absorption contributes to its favorable safety profile for the treatment of intestinal amebiasis.
|
| Toxicity/Toxicokinetics |
Toxicological data for teclozan indicate that it is generally well-tolerated when used for the treatment of intestinal amebiasis. The compound's limited systemic absorption minimizes the risk of systemic toxicity. Common adverse effects may include gastrointestinal disturbances. The compound is for therapeutic use under medical supervision.
|
| References |
[1]. Gonzales MLM, et al. Antiamoebic drugs for treating amoebic colitis. Cochrane Database Syst Rev. 2019;1(1):CD006085. Published 2019 Jan 9.
[2]. Díaz, V. M. M. . Pharmacological Treatment of Giardiasis. In: Rodriguez-Morales, A. J. , editor. Current Topics in Giardiasis [Internet]. London: IntechOpen; 2017. |
| Additional Infomation |
Teclozan belongs to the benzene family of compounds. It is an antiprotozoal drug, commonly used to treat protozoan infections.
Teclozan (WIN 13146) (CAS#: 5560-78-1) is an amebicide used for the treatment of intestinal amebiasis caused by Entamoeba histolytica. The compound acts locally in the intestinal lumen to eliminate the parasite. It is a dichloroacetamide derivative used in antiprotozoal research and clinical treatment. |
| Molecular Formula |
C20H28CL4N2O4
|
|---|---|
| Molecular Weight |
502.26
|
| Exact Mass |
500.08
|
| Elemental Analysis |
C, 47.83; H, 5.62; Cl, 28.23; N, 5.58; O, 12.74
|
| CAS # |
5560-78-1
|
| PubChem CID |
21723
|
| Appearance |
Solid powder
|
| Density |
1.294g/cm3
|
| Boiling Point |
585.8ºC at 760mmHg
|
| Flash Point |
308.1ºC
|
| Index of Refraction |
1.541
|
| LogP |
4.024
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
30
|
| Complexity |
459
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCOCCN(CC1=CC=C(C=C1)CN(CCOCC)C(=O)C(Cl)Cl)C(=O)C(Cl)Cl
|
| InChi Key |
MSJLJWCAEPENBL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H28Cl4N2O4/c1-3-29-11-9-25(19(27)17(21)22)13-15-5-7-16(8-6-15)14-26(10-12-30-4-2)20(28)18(23)24/h5-8,17-18H,3-4,9-14H2,1-2H3
|
| Chemical Name |
Acetamide, N,N'-(1,4-phenylenebis(methylene))bis(2,2-dichloro-N-(2-ethoxyethyl)-
|
| Synonyms |
Teclozan; Falmonox; Teclosine; Teclozine; NSC 107433; Teclosan; Teclosine; Win 13146; Win-13146; Win13146; Win-AM 13146;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 62.5 mg/mL (124.44 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.14 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9910 mL | 9.9550 mL | 19.9100 mL | |
| 5 mM | 0.3982 mL | 1.9910 mL | 3.9820 mL | |
| 10 mM | 0.1991 mL | 0.9955 mL | 1.9910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
